Abstract

The present disclosure concerns a Reg3α polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for protecting oxygen sensitive gram-positive bacteria, compositions including the polypeptide, and their use. The disclosure shows that increasing concentration of the hReg3α lectin into the gastrointestinal tract (GIT) lumen of hReg3α-transgenic mice induced significant changes in composition of gut microbiota, and dramatically improved host resistance to intestinal inflammation. The Reg3α polypeptide may be used for preventing or treating microbiota-related diseases and/or disorders, including inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders, and the prevention and treatment methods may also include transferring to said patient fecal microbiota from a human or animal expressing the Reg3α polypeptide.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A23L 33/19 - Dairy proteins

Abstract

The invention concerns a Reg3α polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for protecting oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide, and their use. The inventors showed that increasing concentration of the hReg3α lectin into the gastrointestinal tract (GIT) lumen of hReg3α-transgenic mice induced significant changes in composition of gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3α exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and the ROS scavenging activity, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that hReg3α-transgenic mice were better able to resist DSS-induced colitis after antibiotherapy. The Reg3α polypeptide may be used for preventing or treating microbiota-related diseases and/or disorders, including inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A23L 33/19 - Dairy proteins

Abstract

An expression cassette including a gene of interest under the control of an inducible promoter, characterized in that said inducible promoter includes at least one CARE regulatory sequence (C/EBP-ATF responsive element) and a minimal promoter. Also, a vector and a host cell, as well as to a pharmaceutical composition including such a cassette, and to the use thereof for treating diseases by gene therapy.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/86 - Viral vectors

Abstract

The present invention concerns a method for culturing a plant, said method comprising a culture step wherein said plant is submitted to repeated thermal cycles, wherein, for each thermal cycle, cool temperature and warm temperature are alternately artificially applied to all or a part of said plant, over a period shorter than natural seasons. The present invention concerns a method for culturing a plant, said method comprising a culture step wherein said plant is submitted to repeated thermal cycles, wherein, for each thermal cycle, cool temperature and warm temperature are alternately artificially applied to all or a part of said plant, over a period shorter than natural seasons. The present invention also concerns a method for producing natural rubber from latex-producing plants, said method comprising the steps of (a) culturing the latex-producing plant by implementing the method of culture of the invention, (b) harvesting part or all of root part of said plant, and (c) extracting natural rubber from the root part harvested at step b).

IPC Classes  ?

• C08C 1/04 - PurifyingDeproteinising
• C08H 8/00 - Macromolecular compounds derived from lignocellulosic materials
• A01H 6/00 - Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy

Abstract

A modulated protein composition is described with improved flavor properties over a vegetable protein. Methods of making a modulated protein composition including the use of a volatile modulating yeast culture to ferment a vegetable protein to produce the modulated protein composition are described. Also disclosed are a fermented vegetable composition made from a modulated protein composition, and ingredients and foods including a fermented vegetable composition or a modulated protein composition.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• A23J 3/00 - Working-up of proteins for foodstuffs
• C12P 7/62 - Carboxylic acid esters
• A23J 3/14 - Vegetable proteins
• A23L 27/00 - SpicesFlavouring agents or condimentsArtificial sweetening agentsTable saltsDietetic salt substitutesPreparation or treatment thereof
• A23L 33/185 - Vegetable proteins

Abstract

The invention relates to the field of monitoring the state of health of bees. More specifically, it relates to a biosensor capable of detecting the qualitative and quantitative modifications in the atmosphere inside the hive in the event of intoxication or diseases within the bee colony. It also relates to a system for remotely monitoring the state of health of a bee colony using such a biosensor.

IPC Classes  ?

• A01K 51/00 - Appliances for treating beehives or parts thereof, e.g. for cleaning or disinfecting

Abstract

Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a method for incorporating at least one amino acid within a composition comprising plant proteins. The method comprises the steps of kneading a mixture of plant proteins with at least one plasticizer and at least one free acid. The mixture is then heated, preferably by static heating at a temperature of 120 to 160 °C, then cooked in water. The invention also relates to a composition obtainable by this method and to foods comprising it.

IPC Classes  ?

• A23L 33/175 - Amino acids
• A23J 3/22 - Working-up of proteins for foodstuffs by texturising
• A23L 33/185 - Vegetable proteins

Abstract

The present invention relates to a method and a unit for preparing a solid material for storing ozone, said method comprising contacting cyclodextrins and/or derivatives of cyclodextrins in solid form with a gas comprising ozone, by means of which a solid material for storing ozone is obtained. The present invention also relates to the material thus prepared and to the uses thereof.

IPC Classes  ?

• C08B 37/16 - CyclodextrinDerivatives thereof
• A61L 2/20 - Gaseous substances, e.g. vapours
• C01B 13/00 - OxygenOzoneOxides or hydroxides in general
• C02F 1/78 - Treatment of water, waste water, or sewage by oxidation with ozone
• C08L 5/16 - CyclodextrinDerivatives thereof

Abstract

PLXDC2PLXDC2PLXDC2 rs927826 polymorphism explaining ~3.7% (p 7.5 10 -15PLXDC2PLXDC2PLXDC2 gene would be suitable for identifying a subject having or at risk of having a coagulation related disorder.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to novel oligogalacturonans having a degree of methylation of 0 and a degree of polymerisation of 1 to 10, and to the use thereof for stimulating defence responses of plants against pathogenic microorganisms.

IPC Classes  ?

• C07H 1/08 - SeparationPurification from natural products
• C07H 7/033 - Uronic acids

Abstract

F.prausnitziiprausnitzii and were shown as deriving from a single Microbial Anti- inflammatory Molecule (MAM). The inventors shows that L-MAM treatment prevented animals from development of High-Fat Diet- induced obesity. L-MAM treated mice significantly gained less weight throughout the gavage as compared to HFD-fed control experiment. The difference in body weight between L-MAM-treated animals on a HFD and the remaining animals is largely due to a significant reduction in the percentage of fat mass and a significant increase in the percentage of lean mass. Oral glucose tolerance testing (OGTT) revealed that chronic administration of L-MAM increased glucose tolerance. Finally, all adipose tissues weights were lower in L-MAM- treated mice. Accordingly, the present invention relates to the use of MAM polypeptides for the treatment of obesity and obesity-related disorders.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

MoricandiaMoricandiaMoricandia for the use thereof in the prevention of weight gain, in particular of body fat.

IPC Classes  ?

• A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• A61K 36/481 - Astragalus (milkvetch)
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention relates to a bioelectrochemical reactor (1) which comprises: - an anode chamber (11) having at least two bioanodes (12, 13), and an anodic electrolyte (14) comprising anodic electroactive microorganisms, - a cathode chamber (21) comprising at least one biocathode (22), and a cathodic electrolyte (24) comprising cathodic electroactive microorganisms, - the anode chamber (11) being separated from the cathode chamber (21) by, running from the anode chamber to the cathode chamber, a cation exchange membrane (31) and an anion exchange membrane (32), said cation and anion exchange membranes being separated from each other by an inter-membrane chamber (30), and - means for applying a potential difference between the interconnected bioanodes and the biocathode/biocathodes, the bioanodes and biocathode/biocathodes having active surfaces such that the total active surface of the biocathode/biocathodes (22) is greater than the total active surface of the two bioanodes (12, 13). The invention also relates to a method for regenerating the activity of the bioanodes of the reactor and to the use of said reactor for the electrosynthesis of organic acids and/or alcohols from organic waste.

IPC Classes  ?

• C25B 3/00 - Electrolytic production of organic compounds
• C25B 3/04 - Electrolytic production of organic compounds by reduction
• C25B 9/08 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms
• C25B 11/03 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form perforated or foraminous
• C25B 11/12 - Electrodes based on carbon
• C25B 15/02 - Process control or regulation
• C12P 7/04 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group
• C12M 1/00 - Apparatus for enzymology or microbiology
• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis

Abstract

The present invention relates to allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determine its impact on allergies and/or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+/+) or PCSK9-deficient mice (PCSK9-/-) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer's patches. Moreover, inventors have shown the effect of allergic challenge on primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and/or allergic disease, such as food allergy.

IPC Classes  ?

• A61P 37/08 - Antiallergic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 11/06 - Antiasthmatics

Abstract

The present invention relates to the field of probiotics. More particularly, the present invention relates to a composition comprising at least one bacterial strain pertaining to the genus Propionibacterium for use in the treatment or prevention of mucositis in a subject, preferably for the treatment or prevention of the alteration of tight junctions of epithelial tissue associated with mucositis.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/741 - Probiotics

Abstract

Streptococcus thermophilusStreptococcus thermophilus species with reference CNRZ160 for use in the prevention and/or treatment of intestinal inflammation in an individual.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 1/12 - Antidiarrhoeals
• C12R 1/46 - Streptococcus

Abstract

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. IgA is mainly produced by the gut associated lymphoid tissue (GALT). Both experimental and clinical data suggest a role of the gut microbiota in this disease. The inventors aimed to determine if an intervention targeting the gut microbiota could impact disease development in a humanized mouse model of IgAN, the α1KI-CD89TG mice. Four- week old mice were divided into two groups to receive either antibiotics or vehicle-control by oral gavage twice a week for eight weeks. Antibiotic treatment efficiently depleted the faecal microbiota, impaired GALT architecture and impacted mouse IgA production. However, while hlgA1 and mIgG serum levels were unchanged, the antibiotic treatment markedly prevented hlgA1 mesangial deposition, glomerular inflammation and the development of proteinuria. This was associated with a significant decrease in circulating hlgA1-mIgG complexes. These data support that use of antibiotics would be suitable for the treatment of immunoglobulin A nephropathy.

IPC Classes  ?

• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 38/12 - Cyclic peptides
• A61K 31/65 - Tetracyclines
• A61K 31/18 - Sulfonamides
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins

Abstract

The invention concerns a method for crushing a mineral material, which method comprises: -a step of providing said mineral material to be crushed and at least one grinding aid, said at least one grinding aid is chosen from organic plant materials in order to form a plant grinding aid, - a step of crushing said mineral material in the presence of said at least one grinding aid. And, according to the invention, said at least one grinding aid is composed of particles. And in the course of the crushing step, the at least one plant grinding aid is mixed with the mineral material in a proportion by mass less than 5% of the total mass.

IPC Classes  ?

• B02C 23/06 - Selection or use of additives to aid disintegrating

Abstract

P. aeruginosaP. aeruginosaPorphyromonas catoniaeP. aeruginosaPorphyromonas catoniaePorphyromonas catoniae in a biological sample obtained from said subject.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The present invention relates to a method of treating allergic asthma in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a polypeptide comprising or consisting of a biologically active fragment of the house-dust mite Dermatophagoides pteronyssinus Der p 2.1. Inventors have used a model allergy in a severe asthma allergic (mouse Balbc). They have surprisingly found that when they injected twice the polypeptide derp2.1 in the mouse model after a third asthma attack, the mouse presents a respiratory improvement, reduction of neutrophils and eosinophils in the broncho-alveolar lavage (BAL), an increase of regulators lymphocytes T and reduction of natural killer cells in the BAL. Thus, the polypeptide derp2.1 is a new tool to treat the allergic asthma by a restoration of lung function and reduction of inflammatory environment.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A new apple tree named ‘Inobi’ notable for its attractive fruit, favorable organoleptic qualities and resistance to apple scab. Fruit of ‘Inobi’ is highly colored and has a long shelf life.

IPC Classes  ?

• A01H 5/08 - Fruits
• A01H 6/74 - Rosaceae, e.g. strawberry, apple, almond, pear, rose, blackberry or raspberry

Abstract

P. aeruginosaP. aeruginosaPorphyromonasP. aeruginosaPorphyromonasPorphyromonas genus bacteria in a biological sample obtained from said subject.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to a method of preparing a compound of formula (I), comprising a step of reacting a mixture of at least one phenolic compound of the following formula (III), with at least one base. The invention also relates to a method of preparing polymers, and polymers obtained using this method.

IPC Classes  ?

• C07D 303/28 - Ethers with hydroxy compounds containing oxirane rings
• C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
• C08G 59/50 - Amines

Abstract

The present invention generally relates to the field of celluloses, in particular nanocelluloses, and more particularly to methods for producing cellulosic fibres and defibrillating cellulosic substrates. In particular, the invention relates to methods for defibrillating cellulosic substrates and producing celluloses, in particular nanocelluloses (NC), using a new family of fungal lytic polysaccharide monooxygenases (LPMO).

IPC Classes  ?

• D21C 5/00 - Other processes for obtaining cellulose, e.g. cooking cotton linters
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C08L 1/04 - OxycelluloseHydrocellulose
• D21B 1/02 - Pretreatment of the raw materials by physical or chemical means
• D21H 11/18 - Highly hydrated, swollen or fibrillatable fibres

Abstract

Faecalibacterium prausnitziiRoseburia intestinalisRoseburia intestinalis; pharmaceutical compositions comprising the polypeptide and their use; and the use of this polypeptide for promoting ex vivo growth of oxygen sensitive gram-positive bacteria. The Reg3α polypeptide may be used for preventing or treating microbiota-related disease and/or disorder, particularly selected from inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The present invention relates to the use of an extract of knots from trees belonging to the genus Pinus for the treatment of a pathogenic infection due to at least one oomycete. The invention also relates to the extracts obtained by extraction of knots from trees belonging to the genus Pinus, the process for obtaining same, and also the use thereof as fungicide and/or algicide and especially for the treatment of a pathogenic infection due to at least one oomycete.

IPC Classes  ?

• A01N 65/06 - Coniferophyta [gymnosperms], e.g. cypress
• A01N 27/00 - Biocides, pest repellants or attractants, or plant growth regulators containing hydrocarbons
• A01N 37/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
• A61K 36/15 - Pinaceae (Pine family), e.g. pine or cedar
• A61P 31/10 - Antimycotics

Abstract

The present invention relates to a phycocyanin composition for use in inhibiting bone resorption in humans or animals.

IPC Classes  ?

• A61K 35/748 - Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

Apparatus to acquire an image of roots of a plant located in a target rhizotron, said apparatus comprising: a turntable (12) having a rotation axis (X) and intended to support said target rhizotron; a lightening device (14); an first camera (16) having an optical axis (O) substantially oriented toward said rotation axis (X); a focus sensor (18) arranged so as to provide a measure (M) of at least one parameter of the first camera; a control module (20), configured to receive said measure (M), compare said measure (M) to comparison data (C), and inform an operator accordingly, the comparison data comprising data related to reference rhizotrons different than said target rhizotron, and/or data related to one or several previously acquired images of the target rhizotron.

IPC Classes  ?

• A01G 7/00 - Botany in general
• G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light

Abstract

The present invention relates to a method for detecting the sensitivity of one or more polymers and/or one or more polymer blends to a compound, comprising the steps of: exposing a plurality of individual micro-deposits comprising the polymer(s) and/or polymer blend(s) to the compound; and, with the aid of interferometry, detecting a variation in the appearance of a group of micro-deposits exposed to the compound and/or a variation in the dimensions and/or the refractive index of at least one of the micro-deposits exposed to the compound, linked to an interaction between the polymer(s) and/or polymer blend(s) and the compound.

IPC Classes  ?

• G01N 21/41 - RefractivityPhase-affecting properties, e.g. optical path length
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G01N 21/55 - Specular reflectivity
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator

Abstract

The present invention concerns a process for the preparation of stabilized protein aggregate particles, wherein said process comprises the following steps: a) providing an aqueous solution wherein are dispersed proteins and at least one reducing sugar, b) adjusting the pH of the aqueous solution obtained in step a), to a pH above 7, c) drying the aqueous solution obtained in step b), to form powder particles comprising said proteins and said at least one reducing sugar, d) dry heating said powder particles obtained in step c), to form said stabilized protein aggregate particles.

IPC Classes  ?

• A23C 1/04 - Concentration, evaporation or drying by spraying into a gas stream
• A23C 1/05 - Concentration, evaporation or drying by spraying into a gas stream combined with agglomeration
• A23C 1/08 - Freeze drying
• A23C 1/14 - Concentration, evaporation or drying combined with other treatment
• A23C 1/16 - Concentration, evaporation or drying combined with other treatment using additives
• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives
• A23C 9/154 - Milk preparationsMilk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparationsMilk gels
• A23C 9/156 - Flavoured milk preparations
• A23C 9/16 - Agglomerating or granulating milk powderMaking instant milk powderProducts obtained thereby
• A23C 21/06 - Mixtures of whey with milk products or milk components
• A23C 21/08 - WheyWhey preparations containing other organic additives, e.g. vegetable or animal products
• A23J 3/00 - Working-up of proteins for foodstuffs
• A23J 3/04 - Animal proteins
• A23J 3/08 - Dairy proteins
• A23J 3/14 - Vegetable proteins
• A23L 33/17 - Amino acids, peptides or proteins
• A23L 33/185 - Vegetable proteins
• A23L 33/19 - Dairy proteins
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates

Abstract

The present invention relates to a novel process for biological detection of mycobacteria via electrochemical analysis methods of the catalytic activity of antigen 85.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• C12R 1/32 - Mycobacterium
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means

Abstract

The invention relates to a method for preventing metabolic disorders linked to an unbalanced diet at adult age in offspring or to a method for stimulating the intestinal endocrine function and for increasing the sensitivity of the pancreas with respect to glucose at adult age in a mammal, or for preventing glucose homeostasis insufficiency at adult age in a mammal or to a method for reducing sensitivity to inflammations at adult age in a mammal, by administration of ScFOS to the female animal during the gestation of said offspring and/or the breastfeeding of said offspring and/or to said offspring for at least two weeks after weaning.

IPC Classes  ?

• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Abstract

A device comprising: - an oscillator (16) suitable for setting in free oscillation the aerial part of a plant (P) arranged in a test location (E); - a camera (18) for acquiring a series of images of said plant; and - an analysis module (20) for analysing said images, configured to determine, for each of said images and by an analysis of all of the pixels of said image, a property of said image, then to evaluate a characteristic relating to the change over time of said property.

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G06K 9/46 - Extraction of features or characteristics of the image

Abstract

The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

IPC Classes  ?

• C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficieny-associated dysbiosis.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The invention relates to a polysaccharide-oxidizing composition comprising a polysaccharide-oxidizing enzyme wherein, when the said polysaccharide-oxidizing enzyme is compared to the reference polypeptide of SEQ ID NO. 1 as described in the specification by using the BLAST-P comparison method, (i) the said polysaccharide- oxidizing enzyme possesses an amino acid identity of 20 % or more with the said reference polypeptide and (ii) the BLAST-P comparison method results in an E-value of 10 e -3 or less.

IPC Classes  ?

• C12P 19/02 - Monosaccharides
• C07K 14/37 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi
• C12F 3/02 - Recovery of by-products of carbon dioxide
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
• C12P 7/02 - Preparation of oxygen-containing organic compounds containing a hydroxy group
• C12P 7/26 - Ketones
• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group
• C12P 13/04 - Alpha- or beta-amino acids
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12P 7/14 - Multiple stages of fermentationMultiple types of microorganisms or reuse for microorganisms
• C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material

Abstract

The instant invention relates to a nucleic acid for the controlled expression of a nucleic acid encoding a pro-apoptotic protein in an individual, comprising: - a regulatory polynucleotide comprising a minimal promoter and at least one AARE (amino acid response element) nucleic acid, said regulatory polynucleotide being activated in an individual upon consumption of a diet deficient in at least one essential amino acid; and - a nucleic acid encoding a pro-apoptotic protein, which is placed under the control of the said regulatory polynucleotide.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The invention relates to a fusion protein comprising a N protein from a virus of the Pneumovirinae subfamily, Pneumovirinae subfamily, useful in immunization and vaccination methods.

IPC Classes  ?

• C07K 14/135 - Respiratory syncytial virus
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus

Abstract

The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.

IPC Classes  ?

• A61K 35/741 - Probiotics
• C12R 1/01 - Bacteria or actinomycetales
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a new class of peptides having antibacterial activity and presentin D-amino acids and their uses. It also relates to a new enzyme presenting a peptide epimeras activity in vitro and in vivo, thereby being useful for modifying peptides in order to change th amino acid configuration from L to D.

IPC Classes  ?

• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/90 - Isomerases (5.)

Abstract

The present invention relates to the use of a biopolymer as a sensitive material in a dielectric gas sensor for water vapor, carbon dioxide, and/or ethanol.

IPC Classes  ?

• G01N 27/22 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
• G01N 33/12 - MeatFish
• B65B 25/00 - Packaging other articles presenting special problems
• G01N 33/02 - Food

Abstract

The present invention relates to a probiotic bacterial strain into which the gene encoding for a peptidoglycan O-acetyltransferase, or oatA gene, is inactivated, for use in the treatment and/or prevention of visceral abdominal inflammatory disorders in an individual.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 15/03 - Bacteria

Abstract

The present invention relates to a method for preparing a probiotic powder comprising at least one probiotic bacterium, said method comprising: a) providing a probiotic biomass composition comprising at least one probiotic bacterium resulting from the culture of said probiotic bacterium in a whey-containing nutrient medium having a total solid content ranging from above 25 % by weight to up to 35 % by weight, based on the total weight of the said whey- containing nutrient medium; b) spray drying or freeze drying the said probiotic biomass provided at step a) so as to obtain the said probiotic powder.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/04 - Preserving or maintaining viable microorganisms
• A61K 35/74 - Bacteria
• A23L 33/195 - Proteins from microorganisms
• A23L 33/19 - Dairy proteins
• A23P 10/40 - Making free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added

Abstract

The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.

IPC Classes  ?

• A61K 35/741 - Probiotics
• C12R 1/01 - Bacteria or actinomycetales
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• C12N 1/20 - BacteriaCulture media therefor
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

The present invention relates to a FGF19 polypeptide for its use as an agent increasing muscle fibers size, in the prevention and/or treatment of muscle atrophy in a mammal body.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61P 21/06 - Anabolic agents

Abstract

The invention concerns an immunogenic composition comprising a polypeptide or a mixture of polypeptides comprising the N-terminal domain of an a-gliadin or a γ-gliadin, or a fragment of the N-terminal domain of an α-gliadin or a γ-gliadin; and at least one physiologically acceptable adjuvant.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The invention relates to a method for propagating yeast, for use in the production of a fermentation product from lignocellulosic biomass, including the steps that consist of: a. providing a reactor; b. placing in contact in said reactor: a population of yeasts capable of metabolising pentoses and hexoses, with 0.2 to 2.0 g of yeast solids per kg of prepared complete medium, raw marc from the pretreatment of the lignocellulosic biomass, with a solids content (MS) of 8 % to 15 %, nutrients, and cellulases, with 5 to 15 mg of proteins per gram of MS; and c. incubating the mixture at a temperature of 25 ºC to 38 °C, preferably 28 ºC to 33 °C, in microaerobiosis, in which the saccharification of the raw marc and the growth of the yeast are carried out simultaneously.

IPC Classes  ?

• C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material

Abstract

The invention concerns a method for producing nanocelluloses from a cellulose substrate comprising cellulose fibres, said method comprising the following sequence of steps: - a step of enzymatic treatment of said cellulose substrate, by bringing same into contact with at least one cleaving enzyme, then - a step of mechanical treatment of said cellulose substrate subjected to said step of enzymatic treatment, in order to delaminate said cellulose fibres and obtain said nanocelluloses, characterised in that said at least one cleaving enzyme is chosen from the enzymes belonging to the family of lytic polysaccharide monooxygenases (LPMOs) capable of achieving cleavage in the presence of an electron donor. The invention also relates to the nanocelluloses obtained according to said method. No figure.

IPC Classes  ?

• D21C 5/00 - Other processes for obtaining cellulose, e.g. cooking cotton linters
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C08L 1/04 - OxycelluloseHydrocellulose
• D21B 1/02 - Pretreatment of the raw materials by physical or chemical means
• D21H 11/18 - Highly hydrated, swollen or fibrillatable fibres

Abstract

The present invention concerns an isolated polynucleotide responsible of haploid induction in maize plants and related processes. Additionally, the invention relates to plants that have been genetically transformed with the polynucleotide of the invention. The invention also relates to a process for screening a mutant plant population for enhanced haploid induction by using said isolated polynucleotide. The invention further relates to molecular markers associated with haploid induction in maize plants and their use in quality control for inducer lines.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• A01H 5/08 - Fruits
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to the use of a cysteine endoprotease or a malt extract for preventing or reducing cloudiness in fermented or non-fermented cereal-based drinks.

IPC Classes  ?

• A23L 2/84 - Clarifying or fining of non-alcoholic beveragesRemoving unwanted matter using microorganisms or biological material, e.g. enzymes
• C12H 1/00 - Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• C12N 9/50 - Proteinases
• C12C 1/18 - Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt
• C12C 5/00 - Other raw materials for the preparation of beer
• C12C 7/14 - Lautering, i.e. clarifying wort

Abstract

The present disclosure concerns a composition comprising yeast cells and at least one polyphenols having a molecular weight above 620 Da, the polyphenols are adsorbed and retained in the cytoplasm of the yeast cell. The present disclosure also concerns using the composition in cosmetic, dermatological, nutritional and / or pharmaceutical fields, as well as in winemaking to protect the wine against oxidation, therefore preserving the wine quality, color and aromas, and as an alternative to ageing of wine on lees.

IPC Classes  ?

• A61K 36/87 - Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
• A61K 36/064 - Saccharomycetales, e.g. baker's yeast

Abstract

The invention relates to the use of a yeast strain overexpressing at least the following genes: the ALK3 gene, at least one of genes ADH2 and ADH5 and at least one of genes FALDH3 and FALDH4, or gene FA01, for the fermentation-based production of carboxylic diacids.

IPC Classes  ?

• C12P 7/46 - Dicarboxylic acids having four or less carbon atoms, e.g. fumaric acid, maleic acid
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12R 1/645 - Fungi
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

Abstract

The transfer device (10) comprises a sampling needle (24), means (26) of moving the needle (24) between the sample support (12) and the analysis device (14), a selector (28) comprising at least first (28A), second (28B) and third (28C) routes, of which the central route (28A) is connected to the sampling needle (24), the selector (28) being able selectively to connect two routes to one another, a sampling syringe (30), connected to the second route (28B) of the selector (28) and a conveying syringe (32), connected to the third route (28C) of the selector (28) and intended to contain an incompressible liquid.

IPC Classes  ?

• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• G01N 1/38 - Diluting, dispersing or mixing samples

Abstract

The present invention relates to an electrochemical method for determining, in vitro, the presence of beta-lactamase-producing bacteria in a sample that may contain said bacteria.

IPC Classes  ?

• G01N 27/48 - Systems using polarography, i.e. measuring changes in current under a slowly-varying voltage
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

The present invention relates to a method for producing a glycosylated synthon or a monomer. Said method includes at least one step of placing at least one glycan-saccharase in the presence of at least one hydroxylated synthon and at least one saccharose. The invention also relates to a method for producing a glyco(co)polymer, including polymerizing at least two monomers separately obtained from the enzymatic glycosylation method according to the invention, and to a method for producing a glyco(co)polymer, preferably a block glyco(co)polymer, including coupling at least two monomers separately obtained from the enzymatic glycosylation method according to the invention.

IPC Classes  ?

• C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
• C12P 19/58 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound through only acyclic carbon atoms to a non-saccharide heterocyclic ring, e.g. bleomycin, phleomycin
• C12P 19/60 - Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
• C08F 120/28 - Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
• C08F 120/58 - Amides containing oxygen in addition to the carbonamido oxygen

Abstract

The present invention relates to a method for manufacturing a cheese-based food product, advantageously a cheese, cheese specialty, or cheese substitute. Said manufacturing method is characterized in that it includes the following consecutive steps: a) a step A) of providing at least one flavoring matrix, the consistency of which ranges from liquid to pasty, said flavoring matrix resulting from a step of cultivating at least one flavor producing microorganism in a culture medium, said step A) also providing a texture matrix, the consistency of which ranges from liquid to pasty, said texture matrix being suitable for providing the texture of said food product; then b) a step B) of mixing said at least one flavoring matrix with said at least one texture matrix; then c) a texturing step C), during which the mixture from mixing step B is subjected to physiochemical texturing conditions that are adjusted according to the final texture sought for said cheese-based food product.

IPC Classes  ?

• A23C 19/05 - Treating milk before coagulationSeparating whey from curd
• A23C 20/00 - Cheese substitutes
• A23L 27/20 - Synthetic spices, flavouring agents or condiments

Abstract

The invention relates to a process for obtaining a conifer bark-base composition enriched with dihydroquercetin or with tannins, comprising the following steps: a) grinding dried shavings of bark from a conifer so as to obtain a ground conifer bark particle material, and b) selecting, from the ground particle material obtained in step a), the fraction of particles:- of smallest size representing at most 40% by weight, relative to the total weight of the ground particle material obtained in step a), this fraction being enriched with tannins; or - of largest size representing at most 50% by weight, relative to the total weight of the ground particle material obtained in step a), this fraction being enriched with dihydroquercetin.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• B02C 23/08 - Separating or sorting of material, associated with crushing or disintegrating
• A61K 36/15 - Pinaceae (Pine family), e.g. pine or cedar

Abstract

The invention relates to a process for obtaining an extruded or laminated dough intended for food for human consumption and/or animal feed, comprising at least the following steps: a) hydrating a flour and/or a semolina, or a mixture of flours and/or semolinas, comprising at least 35% by weight of leguminous plant or of a mixture of leguminous plants, relative to the total dry weight of said flour and/or semolina, or said mixture of flours and/or semolinas, at a temperature below ambient temperature, preferably at a temperature below 15°C, so as to obtain a hydrated flour and/or semolina or a hydrated mixture of flours and/or semolinas; b) kneading the hydrated flour and/or semolina, or the hydrated mixture of flours and/or semolinas, obtained in step a), at a temperature below ambient temperature, preferably at a temperature below 15°C, so as to obtain a kneaded material; and c) extruding or laminating the kneaded material obtained in step b) at a temperature below 55°C, preferably at a temperature between 35°C and 45°C, so as to obtain an extrudate, or preferably at a temperature between 28°C and 30°C, so as to obtain a laminated dough, said process being carried out under conditions appropriate for reducing and/or inhibiting enzymatic reactions, preferably oxidation enzymatic reactions, and non-enzymatic reactions, preferably free-radical non-enzymatic reactions.

IPC Classes  ?

• A23L 7/109 - Types of pasta, e.g. macaroni or noodles
• A23K 10/00 - Animal feeding-stuffs
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23P 20/20 - Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
• A23L 11/00 - Pulses, i.e. fruits of leguminous plants, for production of foodProducts from legumesPreparation or treatment thereof
• A23L 11/30 - Removing undesirable substances, e.g. bitter substances
• A23P 30/20 - Extruding

Abstract

The invention relates to a compound having the following Formula (I), wherein n and m are whole numbers from 0 to 6, selected independently from each other, and R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, selected independently from each other, and are each a hydrogen atom, an -OH group, or a group selected among: - straight, branched, or cyclic C1-C6 alkyl radicals; - straight, branched, or cyclic C2-C6 alkenyl radicals, optionally interrupted by one or more heteroatoms such as O or N and/or substituted by one or more -OH groups; and - ether oxide radicals having 0 to 6 saturated or unsaturated, straight, branched, or cyclic carbon atoms, optionally interrupted by one or more heteroatoms such as O, Si, or N and/or substituted by one or more -OH groups. In Formula (I), at least one R1 through R5 group is an O-methyl oxirane, at least one R6 through R10 group is an O-methyl oxirane, and at least one of the radicals R2, R4, R7, and R9 is an O-methyl. The invention also relates to a preparation method and to uses of the Formula (I) compound.

IPC Classes  ?

• C07D 303/23 - Oxiranylmethyl ethers of compounds having one hydroxy group bound to a six-membered aromatic ring, the oxiranylmethyl radical not being further substituted, i.e.
• A23L 35/00 - Foods or foodstuffs not provided for in groups Preparation or treatment thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• C07D 303/28 - Ethers with hydroxy compounds containing oxirane rings
• C08G 59/24 - Di-epoxy compounds carbocyclic

Abstract

The invention relates to an extraction device comprising an extraction body (14) having a cylinder (30) and a compression piston (32) movable in the cylinder (30), the cylinder (30) and the piston (32) together defining a chamber (34) for receiving the substance, and the cylinder (30) comprising at least one liquid outflow opening ending in said receiving chamber (34). The cylinder (30) extends in a compression direction (C), and the compression piston (32) is arranged such that it slides freely along said compression direction (C) in said cylinder (30).

IPC Classes  ?

• B30B 9/04 - Presses specially adapted for particular purposes for squeezing-out liquid from liquid-containing material, e.g. juice from fruits, oil from oil-containing material using press rams
• B04B 3/02 - Centrifuges with rotary bowls in which solid particles or bodies become separated by centrifugal force and simultaneously sifting or filtering discharging solid particles from the bowl by means co-axial with the bowl axis and moving to and fro, i.e. push-type centrifuges
• B04B 5/10 - Centrifuges combined with other apparatus, e.g. electrostatic separatorsSets or systems of several centrifuges
• B04B 5/04 - Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers

Abstract

The invention relates to a process for producing at least one metabolite of interest by conversion of a pentose in a microorganism, characterized in that said process comprises at least: (i) an operation of culturing a recombinant microorganism expressing a synthetic pathway for pentose assimilation which comprises at least the following steps: a) phosphorylation in position 1 of a pentose chosen from (D)-xylulose and/or (L)-ribulose, b) cleavage of the pentose-1-phosphate obtained at the end of step a), in order to obtain glycolaldehyde and dihydroxyacetone phosphate (DHAP), and (ii) an operation of recovering said at least one metabolite of interest obtained at the end of the culturing operation (i). The invention also relates to an associated microorganism.

IPC Classes  ?

• C12P 7/18 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
• C12P 7/42 - Hydroxy carboxylic acids

Abstract

The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

IPC Classes  ?

• C12R 1/01 - Bacteria or actinomycetales
• A61K 35/741 - Probiotics

Abstract

The present invention relates to the role of the microbiota in the efficacy of cancer treatments with a drug blocking an. immune checkpoint and provides methods and probiotics to improve the efficacy of such a treatment in patients in need thereof. More particularly, the invention pertains to the use of vancomycin or penicillin to modulate the gut microbiota to potentiate the anticancer effects of anti-CTLA4 molecules. B. fragilis or fecal microbial transplantation of a defined composition enriched in immunogenic Bacteroides spp. can also be used as a probiotic to that aim.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61K 35/741 - Probiotics

Abstract

Abelia plant named, ‘ABENOV41’ that is characterized by its an evergreen plant habit in U.S.D.A. Zone 7, its long and floriferous bloom period, blooming from May to October in France, its large flowers that are pink-violet in color and open from deep pink-purple buds, its bracts that are reddish brown in color, and its moderate to vigorous growth habit.

IPC Classes  ?

• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

A method for stimulating vagal neurons as demonstrated by generation of action potentials on these same neurons, wherein electrical pulse trains are periodically applied to electrodes implanted on the anterior and posterior vagus nerve at an entrance of a diaphragm, wherein each electrical pulse train is formed by a plurality of monophasic pulses having a frequency of at least 13.0 kHz.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

A method for stimulating vagal neurons as demonstrated by generation of action potentials on these same neurons, wherein electrical pulse trains are periodically applied to electrodes implanted on the anterior and posterior vagus nerve at an entrance of a diaphragm, wherein each electrical pulse train is formed by a plurality of monophasic pulses having a frequency of at least 13.0 k Hz.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The present invention relates to an antibody against the follicle-stimulating hormone (FSH), said antibody being capable of potentializing FSH and CG bioactivity.

IPC Classes  ?

• C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 38/24 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. HCGLuteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• A61P 5/24 - Drugs for disorders of the endocrine system of the sex hormones
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The present invention relates to a method for preparing a lactose-containing powder. Said method includes the consecutive steps of: a) concentrating a lactose-containing liquid so as to obtain a concentrated liquid having 55% to 65% dry matter content, said concentration Step a) having a duration between 10 and 20 minutes; b) overconcentrating the concentrate obtained from Step a) so as to obtain an overconcentrated material having 75% to 80% dry matter content, said overconcentration Step b) having a duration varying from 2 to 10 minutes; c) granulating the overconcentrate obtained from Step b) by mixing said overconcentrate with a lactose-containing powder, having at least 95% dry matter content, until a granulated powder having dry matter content with at least 85% dry extract is obtained; and d) drying the granulated powder obtained from Step c) so as to obtain a lactose-containing powder having at least 95% dry matter content.

IPC Classes  ?

• A23C 9/16 - Agglomerating or granulating milk powderMaking instant milk powderProducts obtained thereby
• A23C 1/12 - Concentration by evaporation
• A23L 1/00 - Foods or foodstuffs; Their preparation or treatment (preservation thereof in general A23L 3/00)

Abstract

The present invention relates to a polypeptide comprising or consisting of the amino acid sequence SEQ id n°:1, for use in the treatment or prevention of an inflammatory disease. The invention further encompasses a nucleic acid sequence encoding a polypeptide of the invention, a vector comprising a nucleic acid of the invention and a host cell comprising a nucleic acid sequence and/or a vector of the invention, for use in the treatment or prevention of an inflammatory disease. The invention also concerns a pharmaceutical composition or a food composition comprising a polypeptide, a nucleic acid sequence, a vector or a host cell of the invention and a pharmaceutically acceptable carrier or a dairy product, for the treatment of inflammatory disease. The invention also relates a method for the screening of bacteria having immunomodulatory properties.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a portable device for detecting the presence of elements having an ice producing activity, in at least one sample (E). The portable device (1) has a refrigeration unit (2) comprising - a thermally insulated chamber (3) having at least two locations (8) which are each suitable for receiving a receptacle (M) containing one of said samples (E), - means (4) for refrigeration of said chamber (3), - means (5) for measurement of the temperature, - means (6) for regulation of a target temperature within said chamber (3), - means (7) for autonomous electrical power supply of said refrigeration unit (2), - and means (6) for signalling the attainment of said target temperature. According to the invention, said locations (8) each have dimensions suitable, allowing for clearance, for receiving said receptacle (M) consisting of a microtube (M).

IPC Classes  ?

• B01L 7/00 - Heating or cooling apparatusHeat insulating devices
• B01L 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

The present invention concerns a device (1) for evaluating the orosensory perception of a subject. Said evaluation device (1) comprises a body (2) made from an edible material and comprising at least one detachable part (3) which comprises at least one compound of interest that is likely to constitute an orosensory stimulus, and is designed to be separated from a residual part (21) of said body (2) in order to be deposited in the oral cavity of said subject. Said detachable part or parts (3) are arranged in said body (2), forming a monobloc assembly, and are each delimited by a peripheral edge (31), at least a portion of which is rigidly connected to a residual part (21) of the body (2) by a weakened line (32) preferably consisting of a precut line.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• B65D 75/30 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding

Abstract

The present invention relates to ex vivo method for producing outer membrane vesicles (OMVs) by expression or overexpression of the hemolysin F gene (hlyF) in gram-negative bacterium.

IPC Classes  ?

• C12N 1/06 - Lysis of microorganisms
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to the use of a composition comprising at least one saturated free fatty acid and at least one unsaturated free fatty acid as additive, for modifying the mechanical properties of a thermoplastic polymer material. The present invention also relates to an additivated thermoplastic polymer material and to the process for producing same.

IPC Classes  ?

• C08K 5/09 - Carboxylic acidsMetal salts thereofAnhydrides thereof
• C11C 1/10 - Refining by distillation
• C08L 27/06 - Homopolymers or copolymers of vinyl chloride
• C08L 67/00 - Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chainCompositions of derivatives of such polymers
• C08L 77/00 - Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chainCompositions of derivatives of such polymers

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of influenza A virus infection. In particular, the present invention relates to a method for the treatment of influenza A virus (IAV) infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one anti-platelet agent.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The use of a polyhydroxylated polyaromatic compound, in particular of chicoric acid, for combating plant pests and phytosanitary composition comprising chicoric acid.

IPC Classes  ?

• A01N 37/38 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system
• A01N 37/46 - N-acyl derivatives
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01P 7/04 - Insecticides

Abstract

The present invention relates to starch-based stents for use in the treatment of duct obstruction. In particular, the present invention relates to a method for treating a duct obstruction in a subject in need thereof comprising the step of i) removing the duct obstruction of the subject and ii) implanting a starch based stent for maintaining the open duct.

IPC Classes  ?

• A61L 31/04 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61L 31/18 - Materials at least partially X-ray or laser opaque

Abstract

The present disclosure concerns a process for obtaining a variant yeast strain capable of producing less ethanol in an alcoholic fermentation process than its corresponding ancestral strain. The variant yeast strain is obtained by culturing the ancestral strain in the presence of increasing concentrations of a salt capable of causing an hyperosmotic stress to the ancestral yeast strain. The present disclosure also concerns variant yeast strain obtained from this process (for example the variant yeast strain deposited at Institut Pasteur, on January 9, 2014, under accession number CNCM I-4832, the variant yeast strain deposited at Institut Pasteur, on October 18, 2012 under accession number CNCM I-4684, the variant yeast strain deposited at Institut Pasteur, on October 18, 2012 under accession number CNCM I-4685 and/or the variant yeast strain deposited at Institut Pasteur on January 28, 2015 under accession number CNCM I-4952) as well as processes using the variant yeast strain (wine fermentation for example).

IPC Classes  ?

• C12N 1/16 - YeastsCulture media therefor
• C12N 1/36 - Adaptation or attenuation of cells
• C12R 1/865 - Saccharomyces cerevisiae
• C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
• C12G 1/022 - FermentationMicrobiological or enzymatic treatment

Abstract

Process for treating effluents loaded with ammoniacal nitrogen in a single-chamber reactor (R), to remove the ammoniacal nitrogen therefrom, according to which: provided in the reactor is an anode (A) on which a biofilm essentially containing autotrophic bacteria is formed, and a cathode (C), then completely anaerobic conditions are established in the reactor; a volume of effluent to be treated is introduced into the reactor; a potential difference is applied and maintained between the anode and the cathode throughout the duration of the treatment for eliminating the ammoniacal nitrogen.

IPC Classes  ?

• C02F 3/28 - Anaerobic digestion processes
• C02F 3/30 - Aerobic and anaerobic processes
• C02F 101/16 - Nitrogen compounds, e.g. ammonia

Abstract

The present invention relates to a new enzyme able to produce 4-hydroxybenzyl alcohol from the amino acid tyrosine and the use thereof for producing 4-hydroxybenzyl alcohol.

IPC Classes  ?

• C12P 7/22 - Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
• C12R 1/145 - Clostridium
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention relates to a process for in vitro spermatogenesis from male germinal tissue comprising conducting maturation of testicular tissue comprising germ cells in a bioreactor which is made of a biomaterial and comprises at least one cavity wherein the germinal tissue is placed, and recovering elongated spermatids and/or spermatozoa.

IPC Classes  ?

• C12N 5/076 - Sperm cellsSpermatogonia

Abstract

The present invention relates to a radioluminescent compound for radiotherapy and deep photodynamic therapy (Deep PDT), the radioluminescent compound comprising a molecular conjugate made up of a radioluminescent molecule and one photosensitiser, the radioluminescent molecule being suitable for absorbing an X-ray with energy higher than an absorption threshold and for emitting luminescent radiation in the visible domain, and the photosensitiser being suitable for absorbing said luminescent radiation and producing singlet oxygen. According to the invention, the radioluminescent compound is made up of a molecule of lanthanide chlorine (LnCl3); said photosensitiser is selected among the following photosensitisers: Al(III)phthalocyanine, m-THPC, chlorin e6 (Ce6), hypericin, hypocrellin, Nile blue, oxazine 170, oxazine 1, protoporphyrin IX, 7-methoxycoumarin-4-acetic acid, bacteriochlorophyll, and auramine; and said photosensitiser is selected such as to maximise the energy transfer between an X-ray absorbed by the radioluminescent lanthanide 2 and the photosensitiser in order to produce singlet oxygen.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method for the screening of substances that may be useful for the prevention and treatment of infections by Enterobacteriaceae family comprising a step of determining the ability of a candidate substance to inhibit the expression of the gene entD and/or clbA of the Enterobacteriaceae or to inhibit the activity of the protein encoded by the gene entD and/or the gene clbA.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• A61K 38/00 - Medicinal preparations containing peptides
• C12Q 1/10 - Enterobacteria

Abstract

The present invention concerns a system and method of mass spectrometry, comprising the following steps: a. ionising an analyte to form a precursor ion (A) having a mass-to-charge ratio (m/z), in which m represents the mass and z the atomic number; b. activating the precursor ion (A) by interaction with a beam of neutral species, ions, electrons or photons, having an energy chosen on the basis of the physicochemical properties of the precursor ion, said activation being suitable for producing a product ion (B, C) having the same mass m as said precursor ion (A) and an atomic number z' such that z' is a non-zero integer different from z, z' preferably being chosen from z+1, z+2, z+3, z-1, z-2, z-3, the product ion being formed by ionisation, electron detachment, electron capture or transfer without fragmentation; c. separating the product ion (B, C, E, F) having a predefined mass-to-charge ratio (m/z'); d. detecting said product ion (B, C) having the predefined mass-to-charge ratio (m/z').

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• H01J 49/00 - Particle spectrometers or separator tubes

Abstract

The present invention relates to an isolated polypeptide having the capacity to specifically form alpha-1,3 glucosyl unit branchings on an acceptor comprising at least one hydroxyl group and characterized in that said polypeptide comprises i) the motif I of sequence SEQ ID No. 1, ii) the motif II of sequence SEQ ID No. 2, iii) the motif III of sequence SEQ ID NO. 3, iv) the motif IV of sequence SEQ ID No. 4 or derivatives of one or more of said domains, wherein said polypeptide also exhibits the aspartic residue (D) in position 5 of the motif II (SEQ ID No. 2), the glutamic residue (E) in position 6 of the motif III (SEQ ID No. 3) and the aspartic residue (D) in position 6 of the motif IV (SEQ ID No. 4); and to the uses thereof.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)

Abstract

Method for treating a fluid resource (1) using a system comprising p output pump(s) (P 1, P 2), a treatment unit (2) and q input pump (s) (Ρ,, P 2, P 3) comprising: • i/ collecting current concentrations of a component near the output pumps; • ii/ a target flow rate for receipt of fluid by the treatment unit is determined as a function of the collected concentrations and of a treatment unit operating law that connects the rate of treatment of the fluid in the treatment unit and the concentration of the component in the fluid at the outlet of the treatment unit; • iii/ a target pumping flow rate for each output pump is determined as a function of the concentration of said component near said output pump and is transmitted to said output pump; and • iv/ each output pump implements the transmitted target pumping flow rate, the treatment unit implementing the determined target flow rate for receipt of the fluid. A computer program in a processing module (4) and a module for determining pumping flow rate values are also claimed.

IPC Classes  ?

• C02F 1/00 - Treatment of water, waste water, or sewage
• C02F 3/00 - Biological treatment of water, waste water, or sewage
• C02F 103/00 - Nature of the water, waste water, sewage or sludge to be treated

Abstract

The invention relates to a combination including at least (i) fisetin or one of the derivatives thereof, and (ii) docosahexaenoic acid (DHA) or one of the derivatives thereof, to be used for the treatment and/or prevention of disorders associated with bone loss and/or with an imbalance in the ratio of bone formation to resorption. The invention also relates to a composition including said combination for the use thereof as previously described.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A23L 1/00 - Foods or foodstuffs; Their preparation or treatment (preservation thereof in general A23L 3/00)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to a calcium channel isolated from bees, comprising a Cavα channel having a sequence chosen from the group comprising the sequences SEQ ID Nos 1 to 3. The present invention also relates to a calcium channel isolated from bees, comprising a Cavα channel, a Cavα2‑δ regulatory protein having a sequence chosen from the group comprising the sequence SEQ ID Nos 6 to 8 and/or a Cavβ regulatory protein having a sequence chosen from the group comprising the sequences SEQ ID Nos 4, 5 and 107. The present invention also relates to nucleic acid sequences and to vectors comprising these coding sequences, and also to a method for producing these calcium channels and to the uses thereof. The present invention is in particular of use in the agricultural, ecological and chemistry fields and in the beekeeping field. In particular, it is of use for the analysis/identification of the toxicity or of the innocuousness of molecules, for example of chemical molecules, with respect to bees.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention concerns the use of a furfural derivative of formula (I) in which R represents (i) a -CH=CR'1-COR1 group, a group (ii), a group (iii), a group (iv) or a -CHO group and R' represents a hydrogen atom or a (C1-C4)alkyl group, as a chemical vehicle, as a solvent, co-solvent, coalescing agent, crystallisation inhibitor, plasticising agent, degreasing agent, etchant, cleaning agent or agent for increasing biological activity, and more particularly as a solvent. It also concerns phytosanitary formulations or resin-solubilising formulations comprising at least one such furfural derivative of formula (I).

IPC Classes  ?

• C07D 307/46 - Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
• C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 307/54 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 307/56 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
• A01N 43/653 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• A01N 33/18 - Nitro compounds
• A01N 51/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds having the sequences of atoms O—N—S, X—O—S, N—N—S, O—N—N or O-halogen, regardless of the number of bonds each atom has and with no atom of these sequences forming part of a heterocyclic ring
• C08K 5/1535 - Five-membered rings

Abstract

The present invention relates to a monoclonal antibody that is capable of bonding to deamidated gluten proteins and has no cross-reaction with the non-deamidated gluten proteins.

IPC Classes  ?

• C07K 16/16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from plants
• G01N 33/02 - Food
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a polypeptide comprising or consisting of the amino acid sequence SEQ ID NO: l, for use in the treatment or prevention of an inflammatory disease. The invention further encompasses a nucleic acid sequence encoding a polypeptide of the invention, a vector comprising a nucleic acid of the invention and a host cell comprising a nucleic acid sequence and/or a vector of the invention, for use in the treatment or prevention of an inflammatory disease. The invention also concerns a pharmaceutical composition comprising a polypeptide, a nucleic acid sequence, a vector or a host cell of the invention and a pharmaceutically acceptable carrier, for the treatment of inflammatory disease.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention pertains to a method of selecting or identifying probiotic strains capable of altering water absorption in the colon, and the use of same as medications in the treatment and/or prevention of diarrha. The invention particularly relates to the strain Bacillus subtilis CUl for its use in the treatment and/or prevention of diarrha.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 1/12 - Antidiarrhoeals
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention pertains to a method of selecting or identifying probiotic strains capable of altering water absorption in the colon, and the use of same as medications in the treatment and/or prevention of diarrhœa. The invention particularly relates to the strain Bacillus subtilis CUl for its use in the treatment and/or prevention of diarrhœa.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to durum wheat flour wherein the particle size (D90) of at least 90 % of the grains is smaller than 200 µm and wherein the damaged starch content is higher than 8 %.

IPC Classes  ?

• A21D 10/02 - Ready-for-oven doughs, e.g. packaged doughs
• A23L 1/10 - containing cereal-derived products

Abstract

The present invention relates to a process for the production of a powdered dry emulsion containing at least one lipophilic active ingredient, intended for improving the bioavailability of said lipophilic active ingredient, which comprises the following steps: (a) a step of providing an aqueous phase containing at least one emulsifying compound which is protein in nature, chosen from whey proteins, and a lipid phase containing said lipophilic active ingredient(s), (b) a step of forming an oil-in-water emulsion, (c) a step of incorporating at least one saccharide compound into said oil-in-water emulsion resulting from step (b), and (d) a step of eliminating said aqueous phase in order to obtain said powdered dry emulsion.

IPC Classes  ?

• A23D 9/05 - Forming free-flowing pieces
• A23D 7/005 - Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
• A23D 9/007 - Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;
• A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
• A61K 9/107 - Emulsions
• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives

Abstract

The present invention relates to the field of probiotics. More particularly, the present invention relates to a probiotic Lactobacillus plantarum bacterial strain which has a positive effect on the immune system, both in terms of innate immunity and in terms of adaptive immunity. This effect is manifested in particular in the case of influenza. Even more surprisingly, this bacterial strain exhibits resistance to bile salts, which are a stress inherent in the human digestive tract and in particular in the intestines. The present invention also relates to uses of said bacterial strain. Moreover, the present invention relates to a composition containing said strain.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 1/03 - containing additives (A23L 1/05, A23L 1/30, A23L 1/308 take precedence);;
• A61K 35/74 - Bacteria
• C12R 1/25 - Lactobacillus plantarum

Abstract

The invention relates to a composition, advantageously an emulsion or a foam, comprising an internal phase dispersed in a hydrophilic continuous phase, the percentage of the internal phase being higher than 50%. Said emulsion composition contains nanocrystals of a polysaccharide other than cellulose, advantageously chitin, that are located at the interface between said internal phase and said hydrophilic continuous phase.

IPC Classes  ?

• C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
• C08J 9/30 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by mixing gases into liquid compositions or plastisols, e.g. frothing with air
• B01F 17/00 - Use of substances as emulsifying, wetting, dispersing, or foam-producing agents

Abstract

The invention relates to a combination product including, as active substances, at least one inhibitor of the HMG-CoA reductase enzyme and citrulline or a compound that is the bioequivalent thereof, for treating excess weight or obesity and/or the accumulation of body fat. The invention also relates to a cosmetic treatment method for improving or slimming the figure and/or stimulating the loss of excess weight and/or cellulite and/or reducing the accumulation thereof, said method including administering a combination product that includes, as active substances, at least one inhibitor of the HMG-CoA reductase enzyme or a physiologically acceptable salt thereof, and citrulline or a compound that is the bioequivalent thereof, or one of the analogs thereof, and repeating said administration until the desired cosmetic effect has been achieved. Finally, the invention relates to the use of a combination product as defined above for improving or slimming the figure and/or stimulating the loss of excess weight and/or cellulite and/or reducing the accumulation thereof.

IPC Classes  ?

• A61K 8/11 - Encapsulated compositions
• A61K 8/34 - Alcohols
• A61K 8/42 - Amides
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/402 - 1-aryl-substituted, e.g. piretanide
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present invention relates to the use of LBP/BPI polypeptide to prevent and/or treat diseases caused by oomycetes. The present invention also relates to compositions containing LBP/BPI polypeptides to prevent and/or treat diseases caused by oomycetes. The present invention further relates to the preparation of transgenic plants and animals expressing the LBP/BPI polypeptide of the invention. The present invention finally relates to a method for producing the LBP/BPI polypeptide of the invention.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 31/10 - Antimycotics
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The present invention relates to plants of the Cucurbit family and seeds of such plants having an androecious phenotype even though this sex type is not natural in said plants. The invention further relates to the use of the plants and the seeds of plants of the invention. The invention further relates to the nucleic acid sequence responsible for androecy in the plants of the invention and to the polypeptide encoded by said nucleic acid sequence. Finally, the invention relates to methods of identifying the plants and seeds of the invention.

IPC Classes  ?

• A01H 1/04 - Processes of selection
• A01H 5/08 - Fruits
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells